Verve Therapeutics, Inc.
VERV
$5.76
-$0.02-0.35%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 0.20% | -0.66% | -2.19% | -0.79% | -5.67% |
| Total Depreciation and Amortization | -3.08% | 5.22% | 2.14% | 7.58% | 2.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.49% | 20.23% | 2.05% | -3.71% | 33.89% |
| Change in Net Operating Assets | -153.83% | -119.51% | 242.28% | -82.07% | -108.47% |
| Cash from Operations | -3.13% | -15.95% | 20.71% | -5.90% | -244.42% |
| Capital Expenditure | -48.18% | 4.49% | -126.33% | 80.18% | -105.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -46.43% | 85.51% | 175.56% | -514.18% | 37.73% |
| Cash from Investing | -47.99% | 88.43% | 172.42% | -368.14% | 24.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 180,014.29% | -98.88% | -94.53% | -87.19% | 457.09% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 200.00% | 88.86% | -- |
| Cash from Financing | 179,542.86% | -98.92% | -94.29% | -87.18% | 455.66% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -19.56% | 735.39% | 95.63% | -148.49% | 1,443.97% |